Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 109 | 2024 | 20982 | 2.140 |
Why?
|
Antineoplastic Agents, Hormonal | 19 | 2022 | 1520 | 1.510 |
Why?
|
Neoplasms, Hormone-Dependent | 7 | 2014 | 410 | 1.000 |
Why?
|
Aromatase Inhibitors | 9 | 2019 | 513 | 0.920 |
Why?
|
Tamoxifen | 10 | 2019 | 965 | 0.750 |
Why?
|
Receptor, erbB-2 | 20 | 2023 | 2553 | 0.670 |
Why?
|
Estradiol | 9 | 2019 | 1937 | 0.580 |
Why?
|
Mastectomy | 15 | 2022 | 1818 | 0.490 |
Why?
|
Selective Estrogen Receptor Modulators | 2 | 2006 | 131 | 0.480 |
Why?
|
Estrogen Antagonists | 6 | 2005 | 150 | 0.460 |
Why?
|
Receptors, Progesterone | 8 | 2021 | 1129 | 0.440 |
Why?
|
Estrogen Receptor Modulators | 2 | 2011 | 58 | 0.430 |
Why?
|
Receptors, Estrogen | 14 | 2021 | 2208 | 0.420 |
Why?
|
Carcinoma, Lobular | 2 | 2008 | 480 | 0.410 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 36 | 2020 | 11733 | 0.370 |
Why?
|
Anxiety | 9 | 2022 | 4569 | 0.340 |
Why?
|
Androstadienes | 3 | 2008 | 348 | 0.330 |
Why?
|
Nitriles | 5 | 2008 | 971 | 0.330 |
Why?
|
Mastectomy, Segmental | 11 | 2022 | 955 | 0.330 |
Why?
|
Triazoles | 5 | 2008 | 902 | 0.330 |
Why?
|
Sexual Partners | 3 | 2022 | 800 | 0.290 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 2020 | 258 | 0.290 |
Why?
|
BRCA2 Protein | 4 | 2022 | 797 | 0.290 |
Why?
|
Neoplasms, Second Primary | 4 | 2024 | 1052 | 0.290 |
Why?
|
Antineoplastic Agents | 18 | 2021 | 13632 | 0.280 |
Why?
|
Neoplasm Staging | 30 | 2022 | 11119 | 0.260 |
Why?
|
BRCA1 Protein | 4 | 2022 | 1149 | 0.260 |
Why?
|
Female | 127 | 2024 | 392544 | 0.250 |
Why?
|
Prospective Studies | 34 | 2024 | 54435 | 0.230 |
Why?
|
Chemotherapy, Adjuvant | 13 | 2022 | 3512 | 0.230 |
Why?
|
Estrogen Receptor alpha | 2 | 2021 | 582 | 0.230 |
Why?
|
Adult | 91 | 2024 | 221119 | 0.220 |
Why?
|
Quality of Life | 10 | 2024 | 13367 | 0.220 |
Why?
|
Quinazolines | 6 | 2013 | 1371 | 0.220 |
Why?
|
Fluorouracil | 12 | 2014 | 1642 | 0.210 |
Why?
|
Fertility | 3 | 2022 | 768 | 0.200 |
Why?
|
Carcinoma | 3 | 2021 | 2330 | 0.190 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3594 | 0.180 |
Why?
|
Humans | 140 | 2024 | 761208 | 0.180 |
Why?
|
Cyclophosphamide | 15 | 2013 | 2219 | 0.180 |
Why?
|
Adaptation, Psychological | 2 | 2022 | 2632 | 0.180 |
Why?
|
Neoadjuvant Therapy | 3 | 2020 | 2827 | 0.180 |
Why?
|
Gene Expression | 1 | 2013 | 7571 | 0.180 |
Why?
|
Decision Making | 5 | 2019 | 3931 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2022 | 9278 | 0.170 |
Why?
|
Gene Expression Profiling | 4 | 2019 | 9416 | 0.160 |
Why?
|
Young Adult | 24 | 2024 | 59221 | 0.150 |
Why?
|
Doxorubicin | 14 | 2013 | 2224 | 0.150 |
Why?
|
Social Support | 5 | 2022 | 2175 | 0.150 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 518 | 0.150 |
Why?
|
Combined Modality Therapy | 28 | 2022 | 8519 | 0.140 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2019 | 190 | 0.140 |
Why?
|
Carcinoma in Situ | 1 | 2022 | 791 | 0.140 |
Why?
|
Body Image | 3 | 2020 | 639 | 0.130 |
Why?
|
Breast | 3 | 2022 | 1964 | 0.130 |
Why?
|
Parenting | 1 | 2022 | 701 | 0.130 |
Why?
|
Attitude | 1 | 2020 | 771 | 0.130 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2019 | 360 | 0.120 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 926 | 0.120 |
Why?
|
Patient Participation | 2 | 2015 | 1445 | 0.120 |
Why?
|
Neoplasm Metastasis | 13 | 2018 | 4909 | 0.110 |
Why?
|
Reproductive History | 1 | 2015 | 210 | 0.110 |
Why?
|
Biopsy | 5 | 2022 | 6781 | 0.110 |
Why?
|
Hematopoiesis | 1 | 2022 | 2046 | 0.110 |
Why?
|
Clinical Trials as Topic | 7 | 2014 | 8003 | 0.110 |
Why?
|
Mammary Glands, Human | 1 | 2014 | 202 | 0.110 |
Why?
|
Cisplatin | 6 | 2015 | 1652 | 0.100 |
Why?
|
Employment | 1 | 2019 | 1114 | 0.100 |
Why?
|
Radiotherapy | 3 | 2017 | 1499 | 0.100 |
Why?
|
Middle Aged | 58 | 2022 | 220853 | 0.100 |
Why?
|
Amenorrhea | 2 | 2014 | 483 | 0.100 |
Why?
|
Adult Stem Cells | 1 | 2014 | 221 | 0.100 |
Why?
|
Spouses | 1 | 2015 | 284 | 0.100 |
Why?
|
Depression | 4 | 2020 | 8132 | 0.100 |
Why?
|
Methotrexate | 8 | 2005 | 1718 | 0.100 |
Why?
|
Carboplatin | 1 | 2015 | 793 | 0.100 |
Why?
|
Mutation | 8 | 2023 | 30002 | 0.100 |
Why?
|
Tissue Donors | 1 | 2020 | 2335 | 0.090 |
Why?
|
Deglutition Disorders | 1 | 2017 | 627 | 0.090 |
Why?
|
Breast Feeding | 1 | 2019 | 1356 | 0.090 |
Why?
|
Pyridines | 2 | 2020 | 2872 | 0.090 |
Why?
|
Adolescent | 22 | 2024 | 88298 | 0.090 |
Why?
|
Hodgkin Disease | 7 | 1996 | 1379 | 0.090 |
Why?
|
Socioeconomic Factors | 6 | 2021 | 7804 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2014 | 646 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2010 | 629 | 0.090 |
Why?
|
Radiation Injuries | 2 | 2017 | 1191 | 0.080 |
Why?
|
Prognosis | 17 | 2021 | 29687 | 0.080 |
Why?
|
Disease-Free Survival | 8 | 2019 | 6819 | 0.080 |
Why?
|
Deoxycytidine | 1 | 2014 | 878 | 0.080 |
Why?
|
Treatment Outcome | 22 | 2021 | 64681 | 0.080 |
Why?
|
Lymphatic Metastasis | 6 | 2021 | 2913 | 0.080 |
Why?
|
Piperazines | 1 | 2019 | 2522 | 0.080 |
Why?
|
Age Factors | 7 | 2021 | 18384 | 0.080 |
Why?
|
Creatine Kinase | 1 | 1990 | 684 | 0.080 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2011 | 628 | 0.080 |
Why?
|
Live Birth | 2 | 2023 | 511 | 0.080 |
Why?
|
Germ Cells | 2 | 2022 | 632 | 0.080 |
Why?
|
Aged | 39 | 2022 | 169288 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1118 | 0.070 |
Why?
|
Infertility, Female | 1 | 2014 | 761 | 0.070 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2813 | 0.070 |
Why?
|
Survivors | 3 | 2023 | 2369 | 0.070 |
Why?
|
Interpersonal Relations | 1 | 2015 | 1437 | 0.070 |
Why?
|
Medication Adherence | 1 | 2019 | 2175 | 0.070 |
Why?
|
Drug Administration Schedule | 4 | 2015 | 4851 | 0.070 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2011 | 858 | 0.070 |
Why?
|
Postmenopause | 6 | 2005 | 2514 | 0.070 |
Why?
|
Perception | 1 | 2013 | 1198 | 0.070 |
Why?
|
Cohort Studies | 9 | 2024 | 41496 | 0.070 |
Why?
|
Troponin I | 1 | 2011 | 652 | 0.070 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2024 | 4575 | 0.070 |
Why?
|
Pregnancy Outcome | 3 | 2023 | 2923 | 0.070 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 1702 | 0.070 |
Why?
|
Patient Satisfaction | 2 | 2021 | 3453 | 0.070 |
Why?
|
Genetic Testing | 2 | 2016 | 3537 | 0.070 |
Why?
|
Risk Factors | 13 | 2024 | 74239 | 0.060 |
Why?
|
Diagnosis-Related Groups | 1 | 1987 | 448 | 0.060 |
Why?
|
Paclitaxel | 5 | 2013 | 1730 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3434 | 0.060 |
Why?
|
Pregnancy | 6 | 2024 | 29893 | 0.060 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 899 | 0.060 |
Why?
|
Filgrastim | 3 | 2010 | 132 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5662 | 0.060 |
Why?
|
Sexual Behavior | 1 | 2014 | 2189 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7400 | 0.060 |
Why?
|
Time Factors | 9 | 2020 | 39957 | 0.060 |
Why?
|
Taxoids | 1 | 2007 | 668 | 0.050 |
Why?
|
Medical Oncology | 1 | 2015 | 2320 | 0.050 |
Why?
|
North America | 2 | 2024 | 1284 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 3 | 2022 | 17897 | 0.050 |
Why?
|
Diarrhea | 1 | 2010 | 1316 | 0.050 |
Why?
|
Reticulocytes | 2 | 1974 | 288 | 0.050 |
Why?
|
Heterozygote | 2 | 2022 | 2778 | 0.050 |
Why?
|
Aged, 80 and over | 10 | 2020 | 58952 | 0.050 |
Why?
|
Premenopause | 1 | 2006 | 1039 | 0.050 |
Why?
|
Hospitals, Teaching | 1 | 1987 | 1155 | 0.050 |
Why?
|
Parity | 2 | 2015 | 929 | 0.050 |
Why?
|
Cost of Illness | 2 | 2024 | 1936 | 0.050 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 1990 | 1372 | 0.050 |
Why?
|
Lymphoma | 3 | 2017 | 1898 | 0.050 |
Why?
|
Ovary | 1 | 2006 | 957 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3885 | 0.050 |
Why?
|
Cross-Sectional Studies | 5 | 2022 | 26071 | 0.050 |
Why?
|
Antibodies, Monoclonal | 4 | 2011 | 9187 | 0.050 |
Why?
|
Axilla | 2 | 2021 | 624 | 0.050 |
Why?
|
Erythropoietin | 1 | 2005 | 719 | 0.050 |
Why?
|
Genes, BRCA2 | 2 | 2015 | 591 | 0.050 |
Why?
|
Educational Status | 2 | 2019 | 2510 | 0.050 |
Why?
|
Arm | 2 | 2021 | 589 | 0.050 |
Why?
|
Genes, BRCA1 | 2 | 2015 | 754 | 0.040 |
Why?
|
Leukemia, Lymphoid | 1 | 1980 | 311 | 0.040 |
Why?
|
Neutropenia | 1 | 2005 | 885 | 0.040 |
Why?
|
Feasibility Studies | 4 | 2019 | 5250 | 0.040 |
Why?
|
Medication Errors | 1 | 2006 | 783 | 0.040 |
Why?
|
Vinblastine | 3 | 2013 | 488 | 0.040 |
Why?
|
Lung Diseases, Fungal | 1 | 1980 | 125 | 0.040 |
Why?
|
Fear | 2 | 2021 | 1477 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 12676 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2013 | 9025 | 0.040 |
Why?
|
Follow-Up Studies | 14 | 2024 | 39126 | 0.040 |
Why?
|
Ketones | 1 | 2020 | 182 | 0.040 |
Why?
|
Furans | 1 | 2020 | 201 | 0.040 |
Why?
|
Stroke Volume | 2 | 2011 | 5521 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2011 | 3821 | 0.040 |
Why?
|
Polyethylene Glycols | 3 | 2010 | 1187 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 4014 | 0.040 |
Why?
|
Aspergillosis | 1 | 1980 | 242 | 0.040 |
Why?
|
Blood Donors | 1 | 2020 | 345 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2020 | 318 | 0.040 |
Why?
|
Vaginal Diseases | 1 | 2019 | 103 | 0.040 |
Why?
|
Models, Genetic | 1 | 2008 | 3430 | 0.040 |
Why?
|
Survival Rate | 10 | 2010 | 12728 | 0.040 |
Why?
|
Ovariectomy | 2 | 2019 | 614 | 0.040 |
Why?
|
Drug Hypersensitivity | 1 | 2007 | 918 | 0.040 |
Why?
|
Mammaplasty | 2 | 2021 | 1232 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 422 | 0.040 |
Why?
|
Logistic Models | 3 | 2018 | 13249 | 0.040 |
Why?
|
Pregnancy Rate | 1 | 2020 | 648 | 0.040 |
Why?
|
Unemployment | 1 | 2019 | 210 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2022 | 988 | 0.040 |
Why?
|
Anilides | 1 | 2020 | 411 | 0.040 |
Why?
|
Leuprolide | 1 | 2019 | 312 | 0.040 |
Why?
|
Prevalence | 3 | 2020 | 15721 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2011 | 10756 | 0.040 |
Why?
|
Lactation | 1 | 2019 | 397 | 0.030 |
Why?
|
Heartburn | 1 | 2017 | 70 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5828 | 0.030 |
Why?
|
Heart Diseases | 1 | 2009 | 2795 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2021 | 732 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 998 | 0.030 |
Why?
|
Hot Flashes | 1 | 2019 | 330 | 0.030 |
Why?
|
Hormones | 1 | 2020 | 868 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2021 | 1784 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1504 | 0.030 |
Why?
|
Lymph Node Excision | 2 | 2021 | 1270 | 0.030 |
Why?
|
Incidence | 2 | 2024 | 21365 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1751 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2011 | 10218 | 0.030 |
Why?
|
Mediastinum | 1 | 2017 | 267 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12052 | 0.030 |
Why?
|
Disease Progression | 4 | 2019 | 13511 | 0.030 |
Why?
|
Infusions, Intra-Arterial | 5 | 1981 | 221 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2928 | 0.030 |
Why?
|
Actuarial Analysis | 5 | 1996 | 372 | 0.030 |
Why?
|
Anemia, Hypochromic | 1 | 1974 | 63 | 0.030 |
Why?
|
Keratin-14 | 1 | 2014 | 56 | 0.030 |
Why?
|
Keratin-18 | 1 | 2014 | 38 | 0.030 |
Why?
|
Age Distribution | 1 | 2020 | 2871 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2010 | 6504 | 0.030 |
Why?
|
Hepatic Artery | 5 | 1984 | 232 | 0.030 |
Why?
|
Colorado | 1 | 2014 | 165 | 0.030 |
Why?
|
Directive Counseling | 1 | 2015 | 170 | 0.030 |
Why?
|
Forecasting | 1 | 2003 | 2928 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2015 | 6011 | 0.030 |
Why?
|
Radiotherapy Dosage | 7 | 1999 | 2897 | 0.030 |
Why?
|
Models, Psychological | 1 | 2018 | 830 | 0.030 |
Why?
|
Mastectomy, Radical | 1 | 1993 | 19 | 0.030 |
Why?
|
Mastectomy, Simple | 1 | 1993 | 23 | 0.030 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1084 | 0.030 |
Why?
|
Spirituality | 1 | 2018 | 429 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2015 | 662 | 0.030 |
Why?
|
Neoplasms | 5 | 1990 | 22140 | 0.030 |
Why?
|
Retrospective Studies | 11 | 2020 | 80674 | 0.030 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 963 | 0.030 |
Why?
|
Floxuridine | 3 | 1981 | 44 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2020 | 6223 | 0.020 |
Why?
|
Preoperative Period | 1 | 2014 | 551 | 0.020 |
Why?
|
Weight Gain | 1 | 2022 | 2349 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2007 | 5300 | 0.020 |
Why?
|
Preoperative Care | 2 | 2014 | 2241 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 534 | 0.020 |
Why?
|
Lymph Nodes | 2 | 2019 | 3461 | 0.020 |
Why?
|
Child | 6 | 2022 | 80152 | 0.020 |
Why?
|
Body Weight | 1 | 2022 | 4618 | 0.020 |
Why?
|
Digestive System | 2 | 1984 | 244 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3590 | 0.020 |
Why?
|
Electrophoresis | 1 | 1990 | 225 | 0.020 |
Why?
|
Recurrence | 4 | 2015 | 8457 | 0.020 |
Why?
|
Genomic Instability | 1 | 2015 | 709 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2680 | 0.020 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 1980 | 1405 | 0.020 |
Why?
|
Bone Marrow Transplantation | 2 | 1990 | 2692 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2014 | 1822 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 161 | 0.020 |
Why?
|
Cardiac Electrophysiology | 1 | 2009 | 59 | 0.020 |
Why?
|
Double-Blind Method | 4 | 2005 | 12341 | 0.020 |
Why?
|
Delayed Diagnosis | 1 | 2013 | 465 | 0.020 |
Why?
|
Esthetics | 1 | 1991 | 327 | 0.020 |
Why?
|
Mice, SCID | 1 | 2014 | 2621 | 0.020 |
Why?
|
Alkylating Agents | 2 | 1986 | 133 | 0.020 |
Why?
|
Heart Failure | 1 | 2013 | 11701 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1892 | 0.020 |
Why?
|
Social Class | 1 | 2018 | 1993 | 0.020 |
Why?
|
Carmustine | 3 | 1990 | 137 | 0.020 |
Why?
|
Population Surveillance | 1 | 2019 | 2598 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9652 | 0.020 |
Why?
|
Stress, Physiological | 2 | 1974 | 1405 | 0.020 |
Why?
|
Erythropoiesis | 1 | 1972 | 683 | 0.020 |
Why?
|
Pulmonary Wedge Pressure | 1 | 1989 | 275 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6857 | 0.020 |
Why?
|
Survival Analysis | 4 | 2005 | 10088 | 0.020 |
Why?
|
Polyglutamic Acid | 1 | 2007 | 47 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2004 | 16952 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1703 | 0.020 |
Why?
|
Pilot Projects | 4 | 2010 | 8642 | 0.020 |
Why?
|
Genes, erbB-2 | 1 | 2007 | 162 | 0.020 |
Why?
|
Body Mass Index | 2 | 2015 | 12952 | 0.020 |
Why?
|
Heart | 1 | 1999 | 4431 | 0.020 |
Why?
|
Salvage Therapy | 1 | 1993 | 1264 | 0.020 |
Why?
|
Vincristine | 5 | 1991 | 1036 | 0.020 |
Why?
|
Administration, Oral | 1 | 2014 | 4015 | 0.020 |
Why?
|
Fees and Charges | 1 | 1987 | 192 | 0.020 |
Why?
|
Gene Amplification | 1 | 2010 | 1084 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2864 | 0.020 |
Why?
|
Up-Regulation | 1 | 2014 | 4111 | 0.020 |
Why?
|
Prednisone | 6 | 1991 | 1565 | 0.020 |
Why?
|
Technetium Tc 99m Aggregated Albumin | 1 | 1984 | 66 | 0.020 |
Why?
|
Male | 17 | 2022 | 360693 | 0.010 |
Why?
|
Animals | 4 | 2014 | 168079 | 0.010 |
Why?
|
Genotype | 1 | 2019 | 12985 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 2509 | 0.010 |
Why?
|
Lung Neoplasms | 3 | 2017 | 13385 | 0.010 |
Why?
|
Pulmonary Valve Stenosis | 1 | 1985 | 164 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14610 | 0.010 |
Why?
|
Liver Neoplasms | 4 | 1981 | 4309 | 0.010 |
Why?
|
Infusions, Parenteral | 2 | 1981 | 398 | 0.010 |
Why?
|
Metabolic Clearance Rate | 1 | 2004 | 362 | 0.010 |
Why?
|
Self Report | 1 | 2015 | 3727 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26199 | 0.010 |
Why?
|
Phosphatidylethanolamines | 2 | 1974 | 129 | 0.010 |
Why?
|
Boston | 2 | 2005 | 9327 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5425 | 0.010 |
Why?
|
Half-Life | 1 | 2004 | 649 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16575 | 0.010 |
Why?
|
Carcinoid Heart Disease | 1 | 1982 | 10 | 0.010 |
Why?
|
Malignant Carcinoid Syndrome | 1 | 1982 | 30 | 0.010 |
Why?
|
Neoplastic Cells, Circulating | 1 | 1989 | 943 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 3691 | 0.010 |
Why?
|
United States | 2 | 2024 | 72339 | 0.010 |
Why?
|
Gelatin Sponge, Absorbable | 1 | 1981 | 55 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 1985 | 401 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2014 | 3634 | 0.010 |
Why?
|
Emetics | 1 | 1980 | 9 | 0.010 |
Why?
|
Pharmacology, Clinical | 1 | 1981 | 22 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15841 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8837 | 0.010 |
Why?
|
Drug Evaluation | 3 | 1991 | 641 | 0.010 |
Why?
|
Erythrocyte Transfusion | 1 | 2005 | 569 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2014 | 3253 | 0.010 |
Why?
|
Adenocarcinoma | 2 | 1989 | 6341 | 0.010 |
Why?
|
Statistics as Topic | 1 | 1987 | 2359 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2016 | 6585 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2013 | 3200 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15920 | 0.010 |
Why?
|
Area Under Curve | 1 | 2004 | 1636 | 0.010 |
Why?
|
Patient Admission | 1 | 1987 | 1365 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3198 | 0.010 |
Why?
|
Procarbazine | 3 | 1985 | 172 | 0.010 |
Why?
|
Mechlorethamine | 3 | 1985 | 129 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8530 | 0.010 |
Why?
|
Lymphography | 1 | 1979 | 188 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 18926 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2014 | 10422 | 0.010 |
Why?
|
Duodenum | 1 | 1981 | 491 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1998 | 5809 | 0.010 |
Why?
|
Drug Therapy, Combination | 4 | 1983 | 6304 | 0.010 |
Why?
|
Surgery, Plastic | 1 | 1985 | 640 | 0.010 |
Why?
|
Conditioning, Classical | 1 | 1980 | 367 | 0.010 |
Why?
|
Stomach | 1 | 1981 | 697 | 0.010 |
Why?
|
Physicians | 1 | 2015 | 4584 | 0.010 |
Why?
|
Adenoma, Islet Cell | 1 | 1977 | 72 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2012 | 4487 | 0.010 |
Why?
|
Laparotomy | 2 | 1995 | 456 | 0.010 |
Why?
|
Ovarian Neoplasms | 2 | 1986 | 4872 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2009 | 3899 | 0.010 |
Why?
|
Blood Transfusion | 2 | 1974 | 1303 | 0.010 |
Why?
|
Respiratory System | 1 | 1979 | 562 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1998 | 880 | 0.010 |
Why?
|
Ambulatory Care | 1 | 1987 | 2770 | 0.010 |
Why?
|
Radiation Dosage | 1 | 2004 | 1962 | 0.010 |
Why?
|
Edema | 1 | 1999 | 764 | 0.010 |
Why?
|
Osmotic Fragility | 1 | 1974 | 35 | 0.010 |
Why?
|
Phosphorus Radioisotopes | 1 | 1974 | 100 | 0.010 |
Why?
|
Remission Induction | 2 | 1991 | 2392 | 0.010 |
Why?
|
Lung | 2 | 1984 | 9979 | 0.010 |
Why?
|
Erythrocytes | 2 | 1974 | 2413 | 0.010 |
Why?
|
Cell Membrane | 2 | 1974 | 3661 | 0.010 |
Why?
|
Carbon Radioisotopes | 1 | 1974 | 561 | 0.010 |
Why?
|
Abdomen | 1 | 1979 | 1128 | 0.010 |
Why?
|
Isotope Labeling | 1 | 1974 | 393 | 0.010 |
Why?
|
Echocardiography | 2 | 1985 | 5006 | 0.010 |
Why?
|
Splenectomy | 1 | 1974 | 391 | 0.010 |
Why?
|
Lymphocytes | 1 | 1980 | 2603 | 0.010 |
Why?
|
Hemolysis | 1 | 1974 | 415 | 0.010 |
Why?
|
Phosphorus Isotopes | 1 | 1972 | 124 | 0.010 |
Why?
|
Child, Preschool | 4 | 1996 | 42224 | 0.010 |
Why?
|
Chromatography, Thin Layer | 1 | 1972 | 213 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 1991 | 5321 | 0.010 |
Why?
|
Embolization, Therapeutic | 1 | 1981 | 1419 | 0.010 |
Why?
|
Hemorrhage | 2 | 1974 | 3422 | 0.010 |
Why?
|
Carbon Isotopes | 1 | 1972 | 458 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1974 | 2561 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 15308 | 0.010 |
Why?
|
Cytoplasm | 1 | 1974 | 1498 | 0.010 |
Why?
|
Bone Marrow | 1 | 1979 | 2911 | 0.010 |
Why?
|
Bone and Bones | 1 | 1979 | 2568 | 0.000 |
Why?
|
Glycine | 1 | 1972 | 659 | 0.000 |
Why?
|
Hemoglobins | 1 | 1974 | 1525 | 0.000 |
Why?
|
Etoposide | 1 | 1990 | 635 | 0.000 |
Why?
|
Cardiac Tamponade | 1 | 1989 | 175 | 0.000 |
Why?
|
Rats | 2 | 1974 | 23704 | 0.000 |
Why?
|
Liver | 2 | 1979 | 7514 | 0.000 |
Why?
|
Receptors, Steroid | 1 | 1987 | 155 | 0.000 |
Why?
|
Skin | 1 | 1979 | 4473 | 0.000 |
Why?
|
Thiotepa | 1 | 1985 | 66 | 0.000 |
Why?
|
Algorithms | 1 | 2005 | 14025 | 0.000 |
Why?
|
Liver Circulation | 1 | 1984 | 159 | 0.000 |
Why?
|
Microcirculation | 1 | 1989 | 1280 | 0.000 |
Why?
|
Radiotherapy, High-Energy | 1 | 1985 | 228 | 0.000 |
Why?
|
Risk | 1 | 1996 | 9616 | 0.000 |
Why?
|
Melphalan | 1 | 1985 | 420 | 0.000 |
Why?
|
Heart Murmurs | 1 | 1982 | 92 | 0.000 |
Why?
|
Bleomycin | 1 | 1983 | 495 | 0.000 |
Why?
|
Hysterectomy | 1 | 1986 | 857 | 0.000 |
Why?
|
Pulmonary Valve Insufficiency | 1 | 1982 | 140 | 0.000 |
Why?
|
Dacarbazine | 1 | 1983 | 559 | 0.000 |
Why?
|
Colloids | 1 | 1980 | 123 | 0.000 |
Why?
|
Perfusion | 1 | 1984 | 1390 | 0.000 |
Why?
|
Technetium | 1 | 1980 | 326 | 0.000 |
Why?
|
Sulfur | 1 | 1980 | 160 | 0.000 |
Why?
|
Nitrosourea Compounds | 1 | 1978 | 32 | 0.000 |
Why?
|
Physical Examination | 1 | 1985 | 1255 | 0.000 |
Why?
|
Hepatic Veins | 1 | 1978 | 112 | 0.000 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 1982 | 353 | 0.000 |
Why?
|
Tolbutamide | 1 | 1977 | 23 | 0.000 |
Why?
|
Diazoxide | 1 | 1977 | 52 | 0.000 |
Why?
|
Streptozocin | 1 | 1977 | 193 | 0.000 |
Why?
|
Serum Albumin | 1 | 1980 | 674 | 0.000 |
Why?
|
Reoperation | 1 | 1986 | 4303 | 0.000 |
Why?
|
Tissue Distribution | 1 | 1980 | 2263 | 0.000 |
Why?
|
Radionuclide Imaging | 1 | 1980 | 1989 | 0.000 |
Why?
|
Leucine | 1 | 1977 | 546 | 0.000 |
Why?
|
Glucagon | 1 | 1977 | 531 | 0.000 |
Why?
|
Veins | 1 | 1978 | 767 | 0.000 |
Why?
|
Mammography | 1 | 1985 | 2430 | 0.000 |
Why?
|
Gastrointestinal Diseases | 1 | 1981 | 1201 | 0.000 |
Why?
|
Infant | 1 | 1995 | 36169 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 1995 | 15520 | 0.000 |
Why?
|
Blood Glucose | 1 | 1977 | 6392 | 0.000 |
Why?
|
Insulin | 1 | 1977 | 6588 | 0.000 |
Why?
|